The first-ever crowd-sourced small molecule discovery effort has been published in Science, describing the open-science discovery of a novel small molecule targeting SARS-CoV-2 main protease. The COVID Moonshot initiative started as a spontaneous virtual collaboration in March 2020. With the help of more than 200 scientists world-wide, novel compounds with excellent antiviral activity against the main protease of SARS-CoV-2 were identified. The lead candidate is now in pre-clinical evaluation in collaboration with Drugs for Neglected Disease initiative (DNDi).
Dr von Delft said: 'This publication showcases the enormous value that crowd-sourcing can bring to drug discovery. The COVID Moonshot project has been unique in its collaborative approach and commitment to open science and demonstrates that collaboration can be a driver for innovation.' The Science paper has received large press coverage, including articles in MIT Technology Reviews and C&EN (links below).
The discovery platform collaboration that spontaneously formed as the COVID Moonshot now continues its work as the ASAP discovery, which stands for AI-driven Structure-enabled Antiviral Platform, aiming to discover and develop novel broad-spectrum small molecule inhibitors against coronaviruses, flaviviruses and enteroviruses for pandemic preparedness.